PharmAust's new CEO on his journey in biotech and vision for the company
PharmAust (ASX: PAA) chief executive officer Michael Thurn joins Small Caps to discuss his appointment to the company and recent trial developments.
OUR COMPANY
PharmAust is a clinical-stage biotechnology company developing new therapeutics for human and animal health applications. The company is repurposing monepantel for the treatment of cancer in dogs and neurodegenerative diseases in humans.
OUR SCIENCE
Monepantel is an approved veterinary product for the treatment of nematode infestations in sheep. In mammalian cells, monepantel is a potent inhibitor of the mTOR pathway. The mTOR pathway plays a central role in cell growth and proliferation of cancer cells. In degenerating neurons the mTOR pathway autophagic process, or cellular “cleaning process”, where toxic protein is broken down into macromolecules to be reused.
